Epizyme appoints Andrew Singer CFO
This article was originally published in Scrip
Executive Summary
Epizyme, a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers, has appointed Andrew Singer chief financial officer – effective 9 February 2015. Mr Singer was previously managing director of healthcare investment banking at RBC Capital Markets, part of RBC Financial Group.